PhaseBio Pharmaceuticals Profit Margin

As of the most recent data (June 2022), PHAS shows a profit margin of 3402.93%. That compares with -1054.49% in the prior-year period — up 422.7% year over year. That is above the Healthcare sector average of 14.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHAS's profit margin is now 3402.93% (was -1054.49%) — a 422.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether PhaseBio Pharmaceuticals is outperforming or lagging.

The Healthcare sector average profit margin is about 14.34%. PhaseBio Pharmaceuticals is at 3402.93%, which is higher that average. That is roughly 23622.4% above the sector mean. Use the comparison chart on this page to see how PHAS stacks up against individual peers as well.

That compares with -1054.49% in the prior-year period — up 422.7% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare PhaseBio Pharmaceuticals with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has PhaseBio Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 3402.93%) with ownership activity and broader fundamentals.